Significant Progress in CAR-T Therapy in China: Long-Term Effects of Combined CD19 and CD22 Treatment for Acute B-Lymphoblastic Leukemia

### Significant Progress in CAR-T Therapy in China: Long-Term Effects of Combined CD19 and CD22 Treatment for Acute B-Lymphoblastic Leukemia

Leukemia

#ALL #CAR-Ttherapy #Leukemia #CancerResearch #B_ALL #LeukemiaTreatment

Recently, a Chinese medical team published a notable study titled “Five-year outcome of CD19 combined with CD22 CAR-T cell therapy in B-ALL patients relapsed after allo-transplantation.” The research highlights the long-term efficacy of combined CD19 and CD22 CAR-T cell therapy in patients with relapsed acute B-lymphoblastic leukemia (B-ALL) after allogeneic hematopoietic stem cell transplantation (allo-HCT). This breakthrough has not only brought new hope to B-ALL patients but also attracted significant global attention.

**Background and Significance**

Acute B-lymphoblastic leukemia is a hematologic malignancy with poor prognosis, especially for patients who experience relapse after allo-HCT, where survival rates are significantly reduced. CAR-T cell therapy in China has shown increasingly positive results in treating B-ALL, particularly in targeting the CD19 antigen. However, the effects of targeting the CD22 antigen and its potential in combination with CD19 therapy are still under deeper investigation.

**Study Design and Methodology**

Based on a previous phase I clinical trial, this study involved a follow-up of 27 patients who had received CD19 CAR-T treatment. To comprehensively assess the treatment’s efficacy, the study also included three additional patients who experienced relapse with minimal residual disease (MRD) in the bone marrow. Although these patients did not meet the initial trial’s criteria, they received combined CD19 and CD22 CAR-T cell therapy under the same protocol. The CAR-T cells used in this study were second-generation designs created via lentiviral vector transfection.

**Study Results**

After a 5-year follow-up, the Chinese research team found that combined CD19 and CD22 therapy significantly improved patients’ long-term survival rates. Among the 30 patients who completed the combined therapy, the median follow-up time was 64.4 months. After two complete treatment cycles, patients maintained sustained remission. Survival analysis showed that the 3-year and 5-year overall survival rates reached 79% and 75%, respectively, with event-free survival rates of 54% and 50%. These results indicate that combined CD19 and CD22 CAR-T cell therapy offers substantial long-term efficacy for relapsed B-ALL patients.

**Conclusions and Future Outlook**

This study not only validates the potential of CAR-T cell therapy in hematologic malignancies but also provides new therapeutic insights for clinical practice. The combination of CD19 and CD22 holds promise for offering a more effective treatment option for B-ALL patients who relapse after allo-HCT, significantly improving their long-term survival rates.

As research in CAR-T cell therapy deepens, we may see more targeted approaches and optimized treatment protocols emerge. China’s active exploration and innovation in this field bring renewed hope to hematologic cancer patients worldwide, with the expectation that CAR-T therapy will further improve survival rates and quality of life for B-ALL patients in the near future.

To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of Advanced Medicine in China for preliminary evaluation!

WhatsApp: Https://wa.me/+8613717959070

Email: doctor.huang@globecancer.com

 #Immunotherapy #CD19CD22Combo #StemCellTransplant #ChinaMedicalResearch #Hematology #CancerBreakthrough #LongTermSurvival #BloodCancer